Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.
Metrics to compare | FREG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFREGPeersSector | |
|---|---|---|---|---|
P/E Ratio | 16.0x | 12.5x | −0.4x | |
PEG Ratio | 0.10 | 0.13 | 0.00 | |
Price/Book | 1.3x | 1.5x | 2.6x | |
Price / LTM Sales | 1.1x | 1.9x | 3.1x | |
Upside (Analyst Target) | 30.4% | 93.4% | 56.0% | |
Fair Value Upside | Unlock | 29.9% | 9.0% | Unlock |